Ibustar za djecu 20 mg/ml oralna suspenzija Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

ibustar za djecu 20 mg/ml oralna suspenzija

berlin-chemie ag, glienicker weg 125, berlin, njemačka - ibuprofen - oralna suspenzija - 20 mg/ml - urbroj: svaki ml oralne suspenzije sadrži 20 mg ibuprofena

Nurofen za djecu 100 mg/5 ml oralna suspenzija Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

nurofen za djecu 100 mg/5 ml oralna suspenzija

reckitt benckiser d.o.o., ulica grada vukovara 269d, zagreb, hrvatska - ibuprofen - oralna suspenzija - 100 mg/5 ml - urbroj: 5 ml oralne suspenzije sadrži 100 mg ibuprofena

Nurofen za djecu 100 mg/5 ml oralna suspenzija s okusom jagode Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

nurofen za djecu 100 mg/5 ml oralna suspenzija s okusom jagode

reckitt benckiser d.o.o., ulica grada vukovara 269d, zagreb, hrvatska - ibuprofen - oralna suspenzija - 100 mg/5 ml - urbroj: 5 ml oralne suspenzije sadrži 100 mg ibuprofena 1 ml oralne suspenzije sadrži 20 mg ibuprofena

PROSPAN 26 mg/1 pastila pastila Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

prospan 26 mg/1 pastila pastila

salveo d.o.o. sarajevo - Сухи ekstrakt list bršljena - pastila - 26 mg/1 pastila - 1 pastila sadrži: 26 mg suhog ekstrakta lista bršljana (57,5:1). ekstrakcijsko otapalo: 30% etanol (m/m).

Vazkepa Europska Unija - hrvatski - EMA (European Medicines Agency)

vazkepa

amarin pharmaceuticals ireland limited - icosapent ethyl - dislipidemije - sredstva za modifikaciju lipida - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Imatinib Koanaa Europska Unija - hrvatski - EMA (European Medicines Agency)

imatinib koanaa

koanaa healthcare gmbh - иматиниба мезилат - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastična sredstva - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. pacijenti koji imaju niske ili vrlo nizak rizik od recidiva, ne bi trebali primati adjuvantne terapije. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. osim po prvi put prijavljene kronične fazi kml, nema kontroliranih istraživanja pokazuju klinički učinak ili povećava stopu preživljavanja kod te bolesti.

Aspigola s okusom meda i limuna 8,75 mg pastile Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

aspigola s okusom meda i limuna 8,75 mg pastile

bayer d.o.o., radnička cesta 80, zagreb, hrvatska - flurbiprofen - pastila - urbroj: svaka pastila sadržava 8,75 mg flurbiprofena

Combofen za djecu 32 mg/ml + 9,6 mg/ml oralna suspenzija Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

combofen za djecu 32 mg/ml + 9,6 mg/ml oralna suspenzija

swixx biopharma kft., Árpád fejedelem útja 26 – 28, budimpešta, mađarska - paracetamol ibuprofen - oralna suspenzija - urbroj: jedan ml oralne suspenzije sadrži 32 mg paracetamola i 9,6 mg ibuprofena

Combivir Europska Unija - hrvatski - EMA (European Medicines Agency)

combivir

viiv healthcare bv - lamivudin, зидовудин - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - combivir is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection.

Epivir Europska Unija - hrvatski - EMA (European Medicines Agency)

epivir

viiv healthcare bv - lamivudin - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - epivir je indiciran kao dio antiretrovirusne kombinirane terapije za liječenje odraslih osoba i djece s virusom humane imunodeficijencije (hiv).